|Awarded On||September 14, 2022|
|Title||Targeting NHE6 to improve clinical efficacy of daratumumab in myeloma|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The Methodist Hospital Research Institute|
|Principal Investigator/Program Director||Jing Yang|
*Pending contract negotiation
Multiple myeloma (MM) is the second most common blood cancer. A novel FDA-approved antibody-based drug daratumumab (DARA) has shown to improve therapeutic efficacy when combined with common triplet regimens. DARA targets CD38, a protein that is highly expressed on the surface of MM cells; it kills MM cells by triggering antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). However, high-risk MM patients who too often experience relapsed or refractory disease received little benefit from DARA. As a monotherapy, the response rate to DARA remains low. Thus, understanding how MM cells resist to DARA could help us to improve the therapeutic efficacy and surv...